uniQure N.V. 8-K

What Happened

• On March 2, 2026, uniQure N.V. announced its financial results for the quarter and full year ended December 31, 2025 and provided a corporate update via a press release furnished in an 8‑K (Item 2.02). On the same date the company issued a separate press release with a regulatory update concerning AMT‑130, its investigational gene therapy for Huntington’s disease (Item 7.01). Both press releases were furnished as Exhibits 99.1 and 99.2 to the Form 8‑K.

Key Details

• Filing date: March 2, 2026 (Current Report on Form 8‑K).
• Reporting period: Quarter and full year ended December 31, 2025 (financial results announced).
• Program discussed: AMT‑130 — investigational gene therapy for Huntington’s disease; regulatory update disclosed under Regulation FD.
• Press releases furnished as Exhibits 99.1 (financial results/corporate update) and 99.2 (AMT‑130 regulatory update).

Why It Matters

• Investors should note uniQure has publicly reported its recent operating results and separately disclosed a regulatory development for AMT‑130, a key clinical-stage program. The releases are the company’s official source for updated financial metrics and the regulatory status of AMT‑130; review the exhibited press releases for specifics on revenue, expenses, program milestones, and next steps that could affect valuation or clinical timelines.